Modus Therapeutics opens second study site in ongoing Phase IIa CKD-anemia study

STOCKHOLM, SWEDEN – April 2, 2025: Modus Therapeutics Holding AB (“Modus”), a company developing innovative treatments for patients with significant unmet medical needs, today announced the opening of a second study site in its ongoing Phase IIa clinical study evaluating sevuparin for the treatment of anemia in patients with chronic kidney disease (CKD). The new site is located at the Unità di Nefrologia e Dialisi, Istituti Clinici Scientifici Maugeri S.p.A., in Pavia, Italy. The study’s first study site, Centro Ricerche Cliniche di Verona/Policlinico G.B. Rossi, was initiated at study start in Verona in December 2024.

The Phase IIa study is designed to assess the safety, tolerability, and preliminary clinical effects of sevuparin in non-dialysis and dialysis CKD patients with anemia. Opening a second site marks an important milestone in enabling continued efficient patient recruitment and keeping the study on track.

"With two active sites now open in Italy, we are well positioned to advance the first part of the study as planned. It is truly a privilege to work alongside the expert teams at these two renowned Italian clinics, and our partner CRO Latis S.r.l." said John Öhd, CEO of Modus Therapeutics, and continues, " There remains a significant unmet medical need in CKD with anemia, and we are committed to developing sevuparin as a new treatment option for these patients."

Further study updates are expected in the first half of 2025.

Datum 2025-04-02, kl 15:00
Källa MFN
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet